Aaron Cox
Director of Finance/CFO chez HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profil
Aaron L.
Cox is currently the Chief Financial Officer & Executive Vice President at Horizon Therapeutics Plc.
Previously, he worked as a Vice President-Capital Markets at BMO Capital Markets Corp.
He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The University of Chicago Booth School of Business.
Postes actifs de Aaron Cox
Sociétés | Poste | Début |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Director of Finance/CFO | 16/05/2022 |
Anciens postes connus de Aaron Cox
Sociétés | Poste | Fin |
---|---|---|
BMO Capital Markets Corp.
BMO Capital Markets Corp. Investment ManagersFinance BMO Capital Markets Corp. (BMOCMC) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 1817 and is a direct, wholly-owned subsidiary of BMO Financial Corp., which is wholly-owned by Bank of Montreal (TSE: BMO, NYSE: BMO), a Canadian chartered bank. BMOCMC provides investment advisory and portfolio management services to institutional clients only. | Corporate Officer/Principal | - |
Formation de Aaron Cox
University of Notre Dame | Undergraduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
BMO Capital Markets Corp.
BMO Capital Markets Corp. Investment ManagersFinance BMO Capital Markets Corp. (BMOCMC) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 1817 and is a direct, wholly-owned subsidiary of BMO Financial Corp., which is wholly-owned by Bank of Montreal (TSE: BMO, NYSE: BMO), a Canadian chartered bank. BMOCMC provides investment advisory and portfolio management services to institutional clients only. | Finance |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |